Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases

被引：23

作者：

Holtze, Colin ^{[1
]}

Flaherty, Kevin ^{[1
]}

Kreuter, Michael ^{[2
,3
]}

Luppi, Fabrizio ^{[4
]}

Moua, Teng ^{[5
]}

Vancheri, Carlo ^{[6
]}

Scholand, Mary B. ^{[7
]}

机构：

[1] Univ Michigan, Div Pulm & Crit Carc Med, North Campus Res Complex,Bldg 014-G012, Ann Arbor, MI 48109 USA

[2] Heidelberg Univ, Ctr Interstitial & Rare Lung Dis Pneumol & Resp C, Thoraxklin, Heidelberg, Germany

[3] German Ctr Lung Res, Heidelberg, Germany

[4] Univ Hosp, Ctr Rare Lung Dis, Modena, Italy

[5] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA

[6] Univ Catania, Univ Hosp Policlin Vitt Emanuele, Dept Clin & Expt Med, Catania, Italy

[7] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA

来源：

EUROPEAN RESPIRATORY REVIEW | 2018年 / 27卷 / 150期

关键词：

IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; NINTEDANIB; PIRFENIDONE; CLASSIFICATION; UPDATE;

D O I：

10.1183/16000617.0078-2018

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.

引用

页数：6

共 50 条

[1]

Altarum Institute Center for Sustainable Health Spending, 2017, HLTH SECT TREND REP

[2]

[Anonymous], 2002, Am J Respir Crit Care Med, V165, P277304, DOI DOI 10.1164/AJRCCM.165.2.ATS01

[3]

[Anonymous], An aging world: 2015: International Population Reports

[4]

Bendstrup E, 2015, SARCOIDOSIS VASC DIF, V32, P4

[5] Interstitial lung disease: progress and problems [J].

Bourke, S. J. .

POSTGRADUATE MEDICAL JOURNAL, 2006, 82 (970) :494-499

[6]

Centers for Disease Control, HLTH CARE AM TRENDS

[7] Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report [J].

Collard, Harold R. ;

Ryerson, Christopher J. ;

Corte, Tamera J. ;

Jenkins, Gisli ;

Kondoh, Yasuhiro ;

Lederer, David J. ;

Lee, Joyce S. ;

Maher, Toby M. ;

Wells, Athol U. ;

Antoniou, Katerina M. ;

Behr, Juergen ;

Brown, Kevin K. ;

Cottin, Vincent ;

Flaherty, Kevin R. ;

Fukuoka, Junya ;

Hansell, David M. ;

Johkoh, Takeshi ;

Kaminski, Naftali ;

Kim, Dong Soon ;

Kolb, Martin ;

Lynch, David A. ;

Myers, Jeffrey L. ;

Raghu, Ganesh ;

Richeldi, Luca ;

Taniguchi, Hiroyuki ;

Martinez, Fernando J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (03) :265-275

[8] Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in US Medicare Beneficiaries Aged 65 Years and Older [J].

Collard, Harold R. ;

Chen, Shih-Yin ;

Yeh, Wei-Shi ;

Li, Qian ;

Lee, Yuan-Chi ;

Wang, Alan ;

Raghu, Ganesh .

ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (07) :981-987

[9] Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey [J].

Cosgrove, Gregory P. ;

Bianchi, Pauline ;

Danese, Sherry ;

Lederer, David J. .

BMC PULMONARY MEDICINE, 2018, 18

[10]

Da Silva Roxane Borges, 2011, Healthc Policy, V6, pe106

← 1 2 3 4 5 →